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Abstract
Background: Limb girdle muscular dystrophies are a group of rare and genetically heterogeneous diseases that
share proximal weakness as a common feature; however they are often lacking very specific phenotypic features to
allow an accurate differential diagnosis based on the clinical signs only, limiting the diagnostic rate using phenotype
driven genetic testing. Next generation sequencing provides an opportunity to obtain molecular diagnoses for
undiagnosed patients, as well as identifying novel genetic causes of muscle diseases. We performed whole exome
sequencing (WES) on 104 affected individuals from 75 families in who standard gene by gene testing had not yielded
a diagnosis. For comparison we also evaluated the diagnostic rate using sequential gene by gene testing for 91
affected individuals from 84 families over a 2 year period.
Results: Patients selected for WES had undergone more extensive prior testing than those undergoing standard
genetic testing and on average had had 8 genes screened already. In this extensively investigated cohort WES
identified the genetic diagnosis in 28 families (28/75, 37%), including the identification of the novel gene ZAK
and two unpublished genes. WES of a single affected individual with sporadic disease yielded a diagnosis in 13/38
(34%) of cases. In comparison, conventional gene by gene testing provided a genetic diagnosis in 28/84 (33%) families.
Titinopathies and collagen VI related dystrophy were the most frequent diagnoses made by WES. Reasons why
mutations in known genes were not identified previously included atypical phenotypes, reassignment of pathogenicity
of variants, and in one individual mosaicism for a COL6A1 mutation which was undetected by prior direct sequencing.
Conclusion: WES was able to overcome many limitations of standard testing and achieved a higher rate of diagnosis
than standard testing even in this cohort of extensively investigated patients. Earlier application of WES is therefore
likely to yield an even higher diagnostic rate. We obtained a high diagnosis rate in simplex cases and therefore such
individuals should be included in exome or genome sequencing projects. Disease due to somatic mosaicism may
be increasingly recognised due to the increased sensitivity of next generation sequencing techniques to detect
low level mosaicism.
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Background
Limb Girdle Muscular Dystrophies (LGMDs) are a clin-
ically and genetically heterogeneous group of more than
30 rare disorders which frequently overlap in their
genetic aetiology and clinical presentations with other
myopathies [1]. Current diagnostic algorithms for LGMDs
include clinical assessment, muscle biopsy and MRI to
direct sequential gene by gene testing [2–4]. However, as
in other rare diseases [5], there is frequently a delay to
diagnosis in LGMDs and other myopathies due to the
large number of genetically distinct diseases [6–8].
Obtaining a genetic diagnosis is crucial for an individual
affected by a rare disease in order to optimise clinical care,
enable accurate genetic counselling as well as curtailing
the ‘diagnostic odyssey’ which may include costly and inva-
sive investigations, inappropriate treatment, and psycho-
logical distress [5, 9–11]. In addition a genetic diagnosis
enables access to natural history studies and interventional
clinical trials, which are increasing and are becoming a
concrete opportunity for some of the LGMDs [12].
Next generation sequencing techniques (NGS) provide
a potential way to overcome diagnostic delays due to
genetic heterogeneity and also the possibility to identify
novel genetic causes of muscle disorders [13, 14]. Several
studies have reported on the application of gene panels
[15–23] or WES [24, 25] for the diagnosis in undiag-
nosed muscle disease, achieving diagnostic rates from 16
to 76%, with the highest diagnostic rate achieved in
patients with no prior genetic testing [26].
In the UK, Highly Specialised Services for rare diseases
are commissioned on a national level, and for LGMDs this
service (referred to in this study as the UK LGMD clinic)
is based in Newcastle upon Tyne. In this diagnostic
advisory service patients with LGMD and related pheno-
types from all over the UK are assessed. The same clinical
centre also provides a clinical service to local patients
with genetic neuromuscular diseases in the North of
England [27]. In this population a genetic diagnosis is
achieved in 63% of individuals with an LGMD pheno-
type, meaning that a third of patients with LGMD
remain undiagnosed [27, 28].
In this study, we performed WES in a cohort of patients
with presenting with limb girdle weakness who had been
evaluated at our centre and in whom extensive investiga-
tions, often taking place over a decade or more, had not
been able to reach a precise diagnosis. We also evaluated
the status quo in terms of genetic testing for referrals to
the UK LGMD clinic in a 2 year period. Our aims were
firstly, to identify genetic aetiology of disease, including
variants in known and novel disease genes, in a cohort of
previously extensively investigated myopathy patients, and
secondly to consider the clinical utility of WES as a diag-
nostic tool in a clinical setting by comparison to diagnos-
tic outcomes using standard gene by gene testing.
Results
WES was performed in 135 individuals (104 affected, 31
unaffected relatives) from 75 families who had been
assessed in the UK LGMD clinic in the past and
remained undiagnosed. Ninety-one affected individuals
from 84 families were investigated using standard
genetic testing procedures at the UK LGMD clinic in
the 24 month period examined.
Patients selected for WES had been more extensively
investigated than those undergoing standard testing
Patients selected for WES had undergone more exten-
sive prior investigations than the cohort attending the
UK-LGMD clinic (Additional file 1: Tables S1 and
Additional file 2: Table S2): muscle biopsy was performed
in at least one individual in 74/84 (88%) of UK LGMD-
clinic families, compared to 74/75 (99%) of WES families;
and the mean number of individual genes tested per fam-
ily was 3 for those undergoing standard testing, com-
pared to 8 genes previously tested in the cohort
selected for WES (Fig. 1a).
We compared clinical characteristics which may
impact on rate of diagnosis, including the inheritance
pattern, serum creatine kinase (CK) levels and age of
symptom onset, between the standard testing and WES
cohort (Fig. 1b). Both cohorts mainly comprised patients
with sporadically occurring disease; the WES cohort had a
higher proportion of families with an autosomal recessive
inheritance pattern (24% compared to 8% in the standard
testing cohort). Similar proportions of patients had
dominant or X-linked inheritance patterns, and rates of
consanguinity were similar between groups (Fig. 1). The
majority of patients in both the WES and standard testing
cohorts had an elevated CK level (59% in standard testing
and 65% in WES cohort). A greater proportion of patients
in the standard testing cohort had adult onset of symp-
toms (59%, compared to 38% in the WES cohort). In the
combined WES and standard testing cohorts the five most
frequently tested genes were sequencing of ANO5,
CAPN3, FKRP, LMNA and sequencing of TTN exons 293
and 308, which are mutation hotspots for Hereditary
Myopathy with Early Respiratory Failure, a relatively
frequent diagnosis in the North of England [29].
A genetic diagnosis was obtained for 37% of patients
using WES and for 33% patients by standard testing
In the WES cohort a genetic diagnosis due to mutations
in a known disease gene were made in 25/75 of families
(Fig. 2), and disease due to mutation(s) in a novel disease
genes (ZAK [30], and two currently unpublished genes)
was made in a further 6 individuals from 3 families (3/75),
making the overall rate of diagnosis 28/75 (37%). Using
standard genetic testing a diagnosis was obtained for 28/84
(33%) families (Fig. 2). Fifteen panel tests were requested
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in 14 families in the standard testing cohort and one
panel test was request in a family in the WES cohort
(details of panel tests are included in Additional file 3).
As a result of panel testing a single family was diag-
nosed with a peripheral neuropathy due to a MFN2
mutation (Additional file 1: Table S1).
A specific family structure was not required for an
individual to be selected for WES, and the majority of
patients included were single individuals with no family
history or additional family members available for
sequencing. The diagnostic rate in sporadically occur-
ring disease was 32% (15/47 families), and where only
index patients’ DNA was available was 34% (13/38
families). The highest diagnostic rate was obtained in
families with an autosomal dominant history, where 6
out of 8 families were diagnosed (75%). In families with
an autosomal recessive inheritance pattern 5 of 17
families were diagnosed (29%). In the nine families
where trio WES data was obtained a diagnosis was
obtained in two families (22%).
Genetic diagnoses made by standard testing
Diagnoses made by standard genetic testing are shown
in Fig. 1a, and include LGMDs as well as diseases with
overlapping phenotypes, such as collagen VI-related
dystrophy (COL6-RD) and myofibrillar myopathies.
Notably diagnoses in three families, of fascioscapulo-
humeral muscular dystrophy (FSHD) types 1 and 2 and
Duchenne manifesting carrier due to an intragenic
deletion, would have been missed by WES given the
limitations of WES currently for detecting copy num-
ber changes or more complex genetic abnormalities
as in FSHD.
Genetic diagnoses made by WES
Disease causing mutations in 17 previously known muscle
disease genes were identified by WES (Fig. 2b). Additional
clinical investigations to evaluate the plausibility of a
diagnosis suggested by WES findings, so-called ‘reverse
phenotyping’, were required in most instances to confirm
the diagnosis indicated by WES (Table 1). The most
Fig. 1 Clinical characteristics and prior testing in the cohorts selected for WES and those undergoing standard testing. a - The number of individual
genes screened by any method per family in WES cohort or standard testing cohorts. b - Comparison of inheritance pattern, serum CK and age of
disease onset in cohort selected for WES or undergoing standard testing. Numbers on columns indicate the percentage of patients or, for inheritance
pattern, families with a characteristic
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frequent genetic diagnosis made by WES was disease due
to mutations in TTN, as this large gene was not routinely
sequenced in the pre-NGS era. Titinopathy phenotypes en-
compass a wide spectrum and in this study distal myopathy
(family WES5), congenital myopathy (families WES18 and
WES23), and LGMD (families WES19, WES29, WES61 –
reported in detail elsewhere [31]).
Explanations for why the genetic diagnoses made by
WES had been missed by standard diagnostic pathways
are summarised in Table 2. In five instances mutations in
known genes were identified in patients with typical
phenotypes where this particular genetic test had not yet
been requested due to the number of candidate diagnoses
associated with a non-specific phenotype. At the time of
Fig. 2 Diagnoses made by standard testing (a) and by WES (b). COL6-RD – Collagen VI related dystrophy, LAMA2 MD –LAMA2 related muscular
dystrophy, TAM – Tubular Aggregate Myopathy, IBMPFTD – Inclusion Body Myopathy with Pagets disease and Frontotemporal Dementia
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Table 1 Confirmed diagnoses made by exome sequencing
ID gene c.DNA change* Protein change Reported Segregation studies / Reverse phenotyping investigations
5 TTN c.107840 T > A p.(Ile35947Thr) reported Present in 3 affected family members / muscle MRI and MB
re-analysis: findings consistent with titinopathy
9 COL6A1 c.957G > T p.(Lys319Asn) reported De novo / Repeated Sanger sequencing in DNA extracted
from blood and from cultured fibroblasts demonstrates
presence of mutation at low level consistent with mosaicism –
see text and Fig. 3
13 PIEZO2 c.2136C > A p.(Met712Ile) novel Present in 4 affected family members / Phenotype consistent
with Distal Arthrogryposis Type 5
18 TTN c.48312 + 2_48,312
+ 15del
ExSS novel De novo ExSS; maternally inherited nonsense / MB re-analysis
consistent with titinopathy
c.1933G > T p.(Glu645a) novel
19 TTN c.107377 + 1G > A ESS reported Variants inherited in trans / MB re-analysis consistent with
titinopathyb
c.97863G > A p.(Trp32621a) novel
23 TTN c.50170C > T p.(Arg16724a) novel novel Both variants present in two affected siblings, and confirmed
in trans / MB re-analysis consistent with titinopathy
c.19091G > A p.(Cys6364Tyr)
25 GMPPB c.860G > A p.(Arg287Gln)
p.(Cys113Tyr)
reported novel Segregation not possible / MB consistent with
dystroglycanopathy
c.338G > A
26 LAMA2 c.611C > T p.(Ser204Phe) novel novel Both variants present in 2 affected siblings, parental DNA not
available / MRI brain demonstrated white matter changes,
skin biopsy immunoanalysis demonstrated laminin α2 partial
absence (previously reported [57])
c.4533delT p.(Gly1512Alafsa83)
TTN c.107377 + 1G > A ESS reported novel Both variants present in 2 affected siblings and confirmed in
trans / MB re-analysis consistent with titinopathyb
29 c.98603delT p.(Phe32868Serfsa11)
30 MYH7 Present in 2 affected family members and one with
non-penetrance / MB reassessment
c.5533 N > T p.(Arg1845Trp) reported
32 LAMA2 c.6992 + 5G > A ExSS novel c.2049_2050delAG maternally inherited, paternal DNA not
available / MRI brain demonstrated white matter changes,
skin biopsy immunoanalysis demonstrated laminin α2
partial absence
c.2049_2050delAG p.(Arg683fs) novel
MEGF10 c.2049_2050delAG p.(Arg683Serfsa21) reported Segregation in unaffected siblings consistent with AR
inheritance in trans / MB re-analysis, muscle MRI
36 c.352 T > C p.Cys118Arg p.(Cys118Arg) novel
c.1426 + 1G > T ESS novel Segregation in unaffected siblings consistent with AR
inheritance / CAPN3 sequenced in prior testing: at that time
c.1746-20C > G was
classified as a benign polymorphism and c.759_761delGAA
was not detected by Sanger sequencing
39 CAPN3 c.759_761delGAA
c.1746-20C > G
p.(Lys254del) reported
ExSS reported
47 COL6A1 c.362A > G p.(Lys121Arg) reported Present in 5 affected family members / muscle MRI consistent
with COL6-RD
49 VCP c.329 N > A p.(Arg110His) reported Present in 4 affected family members / no additional
investigations required
52 COL6A3 c.6265G > C p.(Gly2089Arg) novel Present in 2 affected family members / no additional
investigations required
56 STIM1 c.242G > A p.(Gly81Asp) reported De novo / MB re-analysis, USS abdomen, biochemistry and
haematology parameters assessment identified abnormalities
consistent with STIM1 mutation (reported separately [58])
57 LMNA c.746G > A p.(Arg249Gln) reported De novo / no additional investigations required
59 DNM2 c.1684_1686delAAG p.(Lys562del) reported De novo / MB review
61 TTN c.107377 + 1G > A ESS reported Maternally inherited nonsense, paternal DNA not available / CT
of lower limb muscles and phenotype reviewb
c.87529A > T p.(Lys29177a) novel
62 STIM1 c.262A > G p.(Ser88Gly) novel De novo / MB re-analysis, USS abdomen, biochemistry and
haematology parameters assessment identified abnormalities
consistent with STIM1 mutation (reported separately [58])
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study GMPPB and STIM1 were recently identified
myopathy genes and therefore their testing was not yet
part of routine diagnostic screening. Diagnosis in an
MTM1 manifesting carrier (WES67) and a family with
distal arthrogryposis due to PIEZO2 mutation (WES13)
were missed due to the rarity of these disorders [32–34],
which meant that the necessary genes had not been
selected for screening by standard testing.
In seven instances the explanations for why diagnosis
due to mutation(s) in known genes had not previously
been made were related to the fact that these patients
had been undiagnosed for several years, including
muscle biopsy tissue being lost or unsuitable for further
analysis or biopsy being performed before immunohisto-
chemistry that is now routine was available; reclassifica-
tion of polymorphisms as pathogenic; and historical
screening of a gene (LMNA) using DHPLC rather than
genetic sequencing. On two occasions mutations were
missed by diagnostic Sanger sequencing. These findings
indicate the need to revisit strong candidate genes.
Several patients had not been diagnosed due to the
limitations of phenotype-driven testing. These include
an individual with normal dysferlin expression on immu-
noanalysis who was compound heterozygous for two
missense mutations in dysferlin, a rarely reported pheno-
type which may become more common as genetic testing
may precede muscle biopsy [8, 35]. Similarly one patient
with adult onset symptoms had compound heterozygous
mutations in a congenital myopathy gene, MEGF10
(WES36), who would not have been diagnosed by pheno-
type driven testing as diagnosis in this individual expands
the phenotype associated with mutations in this gene. In
Table 1 Confirmed diagnoses made by exome sequencing (Continued)
65 CAV3 c.136G > A p.(Ala46Thr) reported Present in two affected family members / Additional
immunoanalysis of muscle biopsy demonstrated absence
of caveolin 3
67 MTM1 c.1054-2_1054-1delinsTT ESS novel Segregation not possible / X-inactivation studies
demonstrated skewed X-inactivation, muscle MRI and
MB review consistent with MTM1 manifesting carrier
phenotype
71 DYSF c.895 N > C p.(Gly299Arg) reported Consistent with AR inheritance in trans / MB review and
repeat immunoanalysis
c.2875C > T p.(Arg959Trp) reported
75 SGCG c.787G > A (Hom) p.(Glu263Lys) reported Homozygous in 2 affected siblings and heterozygous in
parents and unaffected sibling / Variant was detected by
prior testing but classified as of uncertain clinical significance.
Muscle biopsy was of inadequate quality to perform
immunoanalysis but phenotype in accordance with
this diagnosis
aAll reported variants are heterozygous except where indicated as Hom – homozygous
bThree families with a shared phenotype and mutation in TTN have been reported separately [30]. ESS – essential splice site; ExSS – extended spice site; MB
re-analysis –including additional relevant Immunoanalysis; MB review – no additional immunoanalysis performed. Reference sequences: CAPN3 ENST00000397163;
CAV3 ENST00000343849; COL6A1 ENST00000361866; COL6A3 ENST00000295550; DNM2 ENST00000389253; DYSF ENST00000258104; GMPPB ENST00000308375;
LAMA2 ENST00000421865; LMNA ENST00000368300; MEGF10 ENST00000508365; MTM1 ENST00000370396; MYH7 ENST00000355349; PIEZO2 ENST00000580640;
SCN9A ENST00000409672; SLC2A1 ENST00000426263; STIM1 ENST00000300737; TTN ENST00000589042; VCP ENST00000417448
Table 2 Reason for disease causing mutation was not identified by standard testing. The reason “Genetic heterogeneity” was selected
when the presenting phenotype was consistent with that reported due to mutations in this gene but had not been previously tested as
several genes are associated with this phenotype
Reason No. of occurrences Genetic diagnoses
Whole gene sequencing not previously available 6 TTN
Genetic heterogeneity 5 COL6A1, COL6A3, VCP, DNM2, SLC2A1
Recent gene discovery 3 STIM1, GMPPB
Specific muscle biopsy immunoanalysis not
originally performed
3 LAMA2 (2 occurrences), CAV3
Polymorphism reclassified as pathogenic 3 SGCG, CAPN3 (2 occurrences)
Mutation missed by Sanger sequencing 2 CAPN3, COL6A1 mosaic
Disease rarity 2 PIEZO2, MTM1 manifesting carrier
Atypical phenotype 2 MEGF10, DYSF
Inheritance pattern misleading 1 MYH7
Mutation missed by previous gene screening
technique (DHPLC)
1 LMNA
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one family (WES30) the apparent inheritance pattern,
with an affected male proband, affected maternal uncle
and unaffected mother, had directed testing to X-linked
genes, but in fact the phenotype was compatible with
autosomal dominant disease due to MYH7 mutation as
identified on WES with non-penetrance in the mother.
Mosaicism in COL6A1 detected by WES
The second most frequent diagnosis made by WES and
also frequently made in the standard testing cohort (Fig. 2)
was collagen VI-related dystrophy (COL6-RD). Patient
WES9 had a typical COL6-RD phenotype, and had had
prior diagnostic Sanger sequencing of COL6A1, COL6A2
and COL6A3 which identified five variants of uncertain
clinical significance (Fig. 3). We observed a discrepancy in
detection of variants in these genes by Sanger sequencing
and by WES (Fig. 3a). Following repeated Sanger sequen-
cing of variants detected by WES we noted that a COL6A1
variant (c.957G > T p.Lys319Asn) detected by WES but
not by initial Sanger sequencing was present at a low level
in DNA from patient blood and cultured fibroblasts but
not in DNA from either parent, consistent with a de novo
mosaic mutation (Fig. 3d). One patient with this mutation
has been previously reported [36] with a more severe
phenotype (loss of ambulation aged 7 years, forced vital
capacity (FVC) of 15% and non-invasively ventilated
aged 11 years) than our patient who is now 25 years old
and remains ambulant with an FVC of 56% at last as-
sessment. There was evidence against the pathogenicity
of the other identified variants in COL6A1, COL6A2
and COL6A3 (Fig. 3). Given that mosaicism for collagen
VI genes is a recently recognised cause of disease [37]
we feel that the de novo mosaic COL6A1 variant is
likely to be the cause of disease in our patient. We
observed asymmetry in the pattern of muscle involve-
ment on muscle MRI (Fig. 3e) and on clinical assessment,
which is atypical for COL6-RD and could be explained by
somatic mosaicism.
Discussion
We performed WES in 75 families presenting with
genetically undiagnosed limb girdle weakness and
compared this to phenotype driven genetic testing in a
cohort of patients investigated in the UK LGMD clinic
over a 2 year period. Our results show that, firstly,
patients with undiagnosed myopathies often undergo a
long and costly diagnostic odyssey; and secondly that
WES was able to outperform standard genetic testing,
even in a cohort of patients who had undergone more
extensive prior testing. Sequential gene by gene testing
is time consuming, with individual tests often taking
several months. In the standard testing cohort 67% of
patients remained undiagnosed 2 years after attending
the UK LGMD clinic, and many of the patients selected
for WES had been symptomatic for more than 10 years.
In this time accurate information about prognosis,
optimal medical management or genetic counselling
was unavailable.
Precisely where in the diagnostic pathway WES
should be undertaken for optimum benefit, has not yet
been defined, although earlier application is likely to
substantially improve the diagnostic rate [19], as is
probable for the diagnosis of other genetic diseases by
WES [9]. Notably, patients selected for WES were
further into the diagnostic journey than those attending
the UK LGMD clinic, with on average 8 genes tested
per family in the WES cohort in comparison to 3 genes
in the standard testing cohort, and it is probable that
earlier application would have increased our diagnostic
rate by WES further. Given the rapid pace of change in
diagnostic genetic testing we do not propose a new
diagnostic pathway at this point, but recommend that
any new NGS based pathway for diagnosis of LGMDs
incorporates assessment by a neuromuscular specialist
clinician to ensure appropriate screening for disease
not likely to be detected by NGS which may also
present with proximal weakness, such as FSHD or
dystrophinopathies, is performed in relevant cases.
Several studies have used a gene panel, rather than
WES or genome sequencing, approach for diagnosis in
neuromuscular disease [15–23], and whether this is
best practice in diagnostics is a topic for debate [13].
Although gene panels may be more cost effective in
terms of cost per gene sequenced than individual
genetic tests, and also have the advantage of greater
depth of coverage in comparison to WES, they are still
phenotype-driven testing and as such require the cor-
rect panel of genes to be selected [13, 38] which may
limit the rate of diagnosis. In this study panel tests were
performed in 15 families (Additional file 1: Tables S1
and Additional file 2: Table S2), and only in one
instance did this identify the cause of disease. The wide
range of genetic diagnoses made in patients who had
undergone WES in this study illustrates the overlap in
phenotypes between several neuromuscular disorders
which is problematic for selecting a specific gene panel.
For example patient WES32 presented with adult onset
proximal weakness with CK >1000 iu/L and was therefore
considered to have an LGMD, but actually had disease
due to LAMA2 mutations (Additional file 1: Table S1),
more usually associated with congenital muscular dys-
trophy. Similarly, patient WES31 and WES67 had adult
onset disease due to mutations in genes typically associ-
ated with congenital myopathies (MEGF10 and MTM1
respectively; Additional file 1: Table S1). Restricting testing
to a narrow phenotype-determined panel of genes may
therefore miss atypical phenotypes or genes with a wide
range of associated phenotypes.
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Patients who remain undiagnosed currently may rep-
resent novel genetic diseases, and obtaining WES data,
in addition to allowing for a large number of genes to be
selected for an initial ‘panel by exome’ approach, then
allows for patients with no likely pathogenic variants in
relevant disease genes to be promptly transitioned to
research for further analysis, as occurred in this cohort
with some success, or into international data sharing
projects to facilitate new disease gene identification [39].
It is also conceivable that some undiagnosed patients
may have acquired forms of muscle disease, for example
immune-mediated necrotizing myopathies including
those due to anti-HMGCR and anti-SRP antibodies,
which are diagnoses with therapeutic implications [40].
Alternatively those remaining undiagnosed may have
intronic mutations not detected by WES. Indeed, the
Fig. 3 Sequencing and muscle MRI in Patient WES9. a – variants in collagen VI genes identified by Sanger sequencing and WES in this patient.
b – Pedigree. c – Visualisation of exome sequencing reads in patient DNA from blood with arrow indicating chr21:47,410,198 G > T (hg19)
corresponding to COL6A1 c.957G > T; d – Sequencing chromatograms in patient DNA and parental DNA with COL6A1 c.957G > T variant
indicated by arrows, height of sequencing peak in patient with DNA extracted from both blood and fibroblasts is lower than expected suggestive
of mosaicism. Fibroblasts were obtained from skin biopsy taken from the right arm, which clinically is less severely affected than the left. e-i – T1
weighted axial MRI images of pelvis and lower limbs. In the pelvis (E) there is diffuse involvement of the gluteus maximus and medium with the left
side more severely affected. In the thighs (F&G) there is sparing of gracilis and vastus medialis on the right, and diffuse involvement of all muscles on
the left. There is central sparing of the vastus lateralis in the thighs and a ‘central shadow’ of increased signal intensity in the rectus femoris on the left
(F&G) and less marked on the right, both of which are typical of COL6-RD [56]. In the calves there is peripheral involvement of the gastrocnemius and
soleus on the left, with less pronounced peripheral involvement of the distal gastrocnemius on the right
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recent identification of a deep intronic COL6A1 muta-
tion in 25% of individuals with a COL6-RD phenotype in
who initial testing for COL6A1, COL6A2 and COL6A3
mutations was negative [41], suggests that such muta-
tions have the potential to account for many patients
undiagnosed by WES.
Explanations for why pathogenic mutations in known
genes were identified by WES but not by standard testing
are relevant to many rare diseases, and include the
dynamic nature of assignment of pathogenicity status, an
issue which is not restricted to variants identified by WES,
and single gene diagnostic testing being unable to keep
pace with the rapid rate of new disease gene discovery and
resultant increasing genetic heterogeneity (Table 2). The
individual with a mosaic COL6A1 mutation highlights the
ability of next generation sequencing techniques to iden-
tify somatic mosaicism at a lower level that Sanger
sequencing. As next generation sequencing becomes more
prevalent this may be an increasingly recognised contribu-
tor to human disease [42–44].
The high proportion of patients diagnosed with patho-
genic TTN mutations in the WES cohort is because it is
only with the advent of NGS that is has been possible to
sequence this very large gene. Titinopathies may account
for a large share of as yet undiagnosed muscle disease
[45] although whether this finding may be restricted to
northern Europe for example, or be globally true
remains to be shown. It is therefore likely that some
patients in the standard testing cohort in this study who
remain undiagnosed may have pathogenic TTN variants.
In addition to those with a diagnosis of titinopathy
reported here, potentially damaging TTN variants were
observed in other patients in whom we did not feel there
was sufficient evidence to define them as pathogenic.
The difficulty of determining pathogenicity of titin vari-
ants is likely to be limiting the diagnosis of titinopathy
to those who fulfil conservative diagnostic criteria, there-
fore this diagnosis may therefore be underreported even
in patients where TTN has been sequenced.
Given the high frequency of rare and truncating titin
variants in the general population functional confirm-
ation of pathogenicity of titin variants should be under-
taken [46], as was performed and reported separately for
families WES19, WES29 and WES61 [31]. Such specia-
lised analysis is not routinely available for all patients
with truncating titin variants within the service provided
by the UK Highly Specialised Service (HSS) for LGMD.
Nonetheless we felt that following multidisciplinary
evaluation of genetic and segregation data, clinical fea-
tures, muscle MRI and muscle biopsy histopathology
and immunoanalysis (Additional file 3: Fig. S1) that
affected individuals in families WES18 and WES23, in
who truncating titin variants were also identified, were
most likely affected by titinopathies. It would be prudent
to continue to review assessments of pathogenicity of
TTN variants as our understanding of the complexities
of this gene improves. Critical to this are collaborative
efforts to share data and define a strategy for accurate
interpretation [46, 47].
WES in this study was performed on a research basis
and therefore with no specific cost for comparison, but
in general WES rates vary by sequencing provider and
according to the degree of interpretation. The real cost
in terms of time taken to interpret, confirm and segre-
gate variants as well as clinical assessment +/−additional
investigations to assess plausibility of a diagnosis sug-
gested by WES is however not currently quantified, and
there is concern that these costs may be substantial [48].
Reverse phenotyping investigations, such as additional
muscle biopsy immunoanalysis or muscle MRI were
required in the majority of cases in this study (Table 1),
illustrating that sequencing findings in isolation are
usually insufficient to confidently confirm a diagnosis.
Whether so-called incidental findings [49] are also
reported will also effect this end cost [50].
Our experience of the application of WES in undiag-
nosed myopathies was favourable in comparison to
sequential gene testing, but a detailed cost-benefit
analysis of WES was out with the scope of this study.
Studies addressing this question in other clinical scenarios
are underway [51, 52]. In addition to the readily quantifi-
able expenses of confirmatory investigations or on-going
genetic testing, any cost-benefit analysis of WES must
consider the non-economic cost of remaining undiag-
nosed for several years and the psychological burden this
places on individuals and families, in addition to the
potential missed opportunities for diagnosis-specific inter-
ventions, involvement in clinical trials and ability to make
informed reproductive choices [5, 11]. In rare diseases,
where recruiting sufficient patients for clinic trials can be
a barrier, each newly diagnosed person may contribute to
advancement of translational research activities.
Conclusions
Our results demonstrate the power of WES to provide
diagnoses in patients with undiagnosed limb girdle weak-
ness, including in singleton patients, with a clear advan-
tage over sequential single gene testing in a cohort of
clinically comparable patients. Earlier application of WES
in the diagnostic pathway would be likely to substantially
reduce time to diagnosis and may also reduce the costs
incurred by ongoing investigations, as well as affording
opportunities for detection of low level mosaicism and
novel disease gene identification. As WES, or whole
genome sequencing in the future, becomes increasingly
commonplace the challenge will be to optimise its applica-
tion in order to rationalise diagnostic investigations and
provide a timely diagnosis for patients.
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Methods
Evaluation of standard genetic testing
Sequential gene by gene testing and gene panels as were
routinely available within the National Health Service
(NHS) during the time period examined are referred to
as “standard testing”. Details of the gene panels used are
included in Additional file 1: Tables S1 and Additional
file 2: Table S2. There was no LGMD gene panel avail-
able for diagnostic use through the NHS during the
period studied. Data, including genetic tests performed,
serum CK level, age of symptom onset, inheritance
pattern and whether a muscle biopsy was performed,
was collected for all undiagnosed patients attending the
UK-LGMD clinic from 1st April 2013 to 31st March
2015. Six patients attending clinic in this time period
underwent WES as part of this research study and there-
fore their data have been excluded from the analysis of
standard genetic testing. All investigations were performed
as part of standard clinical care.
Patient selection for exome sequencing
Patients were selected from a database of those attending
the UK-LGMD clinic between 2002 to present day.
Individuals presenting with limb girdle weakness of a
probably genetic aetiology who had been assessed by
our neuromuscular specialist clinic at any time since
2002, and in whom genetic testing to date was negative,
were selected. Priority was given to family structures
likely to be most informative, for example those con-
sistent with autosomal recessive inheritance or consan-
guineous families; however such families were relatively
uncommon in this cohort of patients.
Exome sequencing and bioinformatics
Affected individuals underwent WES; in families with
apparent autosomal recessive inheritance two affected
siblings were sequenced, and in those with autosomal
dominant inheritance two affected family members were
sequenced. If this did not yield a diagnosis additional af-
fected or unaffected family members were subsequently
sent for WES as appropriate.
WES in 30 individuals (20 affected, 10 unaffected) from
9 families was performed at de CODE genetics (Iceland)
using Illumina Nextera Rapid Capture exome kit (37 Mb)
and sequenced 90 nt paired-end on Illumina HiSeq2000 se-
quencer. WES in a further 104 (84 affected, 20 unaffected)
individuals from 65 additional families was performed at
the Genomics Platform at the Broad Institute of Harvard
and MIT (Cambridge, MA, USA), with Agilent Sure-Select
Human All Exon v2.0 (44 Mb) on Illumina HiSeqXs plat-
form (Illumina, Inc. San Diego, CA). Sequence alignment,
variant calling and functional annotation were performed
with Burrows Wheel Aligner, Genomes Analysis Tool Kit
and Variant Effect Predictor (VEP).
Variant filtering and correlation with phenotype
Analysis of WES data was with proprietary software from
deCODE genetics (Clinical Sequence Miner) and The
Broad Institute (xBrowse) respectively. Variants were
filtered to include those that were rare (MAF <0.01) in
publically available reference datasets (ExAC and 1000
Genomes) and predicted to be moderately-severely dam-
aging by VEP. Analysis was initially performed to identify
variants in known muscle disease genes (www.musclegen-
etable.fr). Where a putatively pathogenic variant in a
known gene was identified this was evaluated according to
current guidelines including assessment of frequency, in
silico predictions of pathogenicity, review of previous
reports of patients with same variants, and published
experimental work to review the effect of a variant on
protein function [53, 54].
Putative genetic diagnoses were correlated with clinical
findings including for example muscle MRI, clinical review
of phenotype and assessment for extra-neuromuscular
features as suggested by genotype. Where relevant and
possible genetic diagnoses were correlated with histopath-
ology phenotype, by identification of characteristic findings
on muscle biopsy histopathology and immunoanalysis
using antibodies typically using a standard dystrophy panel
[55] as carried out by the diagnostic service provided by
the Muscle Immunoanalysis Unit, which is part of the
UK HSS LGMD referral service. Genetic findings,
clinical features, muscle MRI and muscle biopsy results
were then integrated at a multidisciplinary meeting to
reach a consensus as to whether variants were likely to
be disease causing.
In the absence of a positive diagnosis due to mutation
in a known muscle disease gene additional affected or
unaffected family members underwent WES and likely
inheritance pattern and the scope of variant analysis was
widened to include variants in novel genes.
Additional files
Additional file 1: Table S1. Summary details of affected individuals
included in WES cohort. (PDF 295 kb)
Additional file 2: Table S2. Summary details of affected individuals
included in standard testing cohort. (PDF 272 kb)
Additional file 3: Figure. S1. Clinical details and muscle biopsy findings
in families diagnosed with titinopathies. (PDF 340 kb)
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